Since the rapid growth of microvessels can increase plaque in patients with carotid stenosis, it is important to identify a maker for microvessels. CD31 and CD105 are the possible markers studied in this experiment, and it turns out that CD105 is better for detecting microvessels in plaque.
This study aims to determine if CD31 or CD105 is a better marker for microvessels.
Finding a good marker for carotid plaques is really important for the treatment of carotid stenosis, which can have very serious complications. CD31 and CD105 were chosen for this study because they were known markers for microvessels.
The average microvessels counted after CD31 staining was 5.8, and the average for CD105 was 9.2. In patients with diabetes, CD105 stained significantly more microvessels than patients with other conditions. Patients with hypertension and hyperlipidemia also had more microvessels stained by CD105, but this difference was not significant.
CD105 was shown to be the better marker in this study. CD105 is also known for being involved in tumor angiogenesis and interacting with Transforming Growth Factor-beta. The buildup of coronary artery plaques can cause stroke when there is a complication called intraplaque hemorrhage. Intraplaque hemorrhage is caused by the disruption of microvessels, which is why identifying CD105 as a marker for microvessels is so important. Immature and fragile microvessels may be more likely to hemorrhage, which may be why we see an increase in CD105 in patients with diabetes.
Samples were collected from patients who had undergone surgery to remove plaque from their carotid artery. Immunohistochemistry was used to assess how well CD31 and CD105 antibodies had stained the microvessels, therefore determining their success as a marker.
CD105 is a better marker than CD31 for microvessels in patients affected by carotid stenosis, and CD105 is highly expressed in diabetic carotid stenosis patients.